UK-based biopharmaceutical company Ananda Pharma plc (AQSE: ANA) ( OTCQB: ANANF) announced on Monday that its Phase I clinical trial for MRX1 has been acknowledged by Australia's Therapeutic Goods Administration (TGA) under the Clinical Trial Notification scheme, enabling expedited trial commencement following Human Research Ethics Committee approval.

MRX1, Ananda's lead investigational cannabidiol formulation, targets complex chronic inflammatory pain conditions and is produced from high-purity, pharmaceutical-grade CBD.

The open-label, multiple-dose Phase I trial aims to assess the pharmacokinetics, safety, tolerability and food effect of MRX1 in healthy adults, providing critical data to support future regulatory submissions and dose optimisation.

Ananda Pharma develops regulatory-approved cannabinoid medicines for chronic conditions such as epilepsy, endometriosis and chemotherapy-induced pain, collaborating with leading scientists and institutions including the University of Edinburgh, Great Ormond Street Hospital for Children, and University College London.